NCT01465334View on ClinicalTrials.gov

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

PHASE2TerminatedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2017

Conditions

CLLSLL

Interventions

DRUG

Ofatumumab

DRUG

High-Dose Methylprednisolone

DRUG

Alemtuzumab

Trial Locations (2)

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

GlaxoSmithKline

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT01465334 - Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL | Biotech Hunter | Biotech Hunter